MARKET

RNAZ

RNAZ

Transcode Therapeutics Inc
NASDAQ
8.91
-1.06
-10.63%
After Hours: 8.56 -0.35 -3.93% 19:59 02/06 EST
OPEN
9.89
PREV CLOSE
9.97
HIGH
10.08
LOW
7.99
VOLUME
161.96K
TURNOVER
--
52 WEEK HIGH
399.00
52 WEEK LOW
6.08
MARKET CAP
8.17M
P/E (TTM)
-0.0252
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 2d ago
TransCode Therapeutics Advances Phase 2a Colorectal Cancer Trial
TipRanks · 2d ago
Transcode Therapeutics In Collaboration With Quantum Leap Healthcare Collaborative, Submitted An FDA Investigational New Drug Application Amendment For Planned Phase 2A Trial With Transcode's TTX-MC138
Benzinga · 2d ago
Transcode Therapeutics, Quantum Leap submit IND for Phase 2a trial of TTX-MC138
TipRanks · 2d ago
TransCode Therapeutics Submits IND Amendment for Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Reuters · 2d ago
TRANSCODE THERAPEUTICS AND QUANTUM LEAP ANNOUNCE SUBMISSION OF IND AMENDMENT FOR PHASE 2A CLINICAL TRIAL WITH TTX-MC138
Reuters · 2d ago
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138
Barchart · 3d ago
Weekly Report: what happened at RNAZ last week (0126-0130)?
Weekly Report · 6d ago
More
About RNAZ
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.

Webull offers Transcode Therapeutics Inc stock information, including NASDAQ: RNAZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNAZ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNAZ stock methods without spending real money on the virtual paper trading platform.